Applied Clinical Trials Digital Edition - July 2011

Article

Applied Clinical Trials

Applied Clinical TrialsApplied Clinical Trials-07-01-2011
Volume 20
Issue 7

CRO/SPONSOR : Personalized Medicine Development - Role of CROs TRIAL DESIGN : Eye Movements Help Determine Side Effect Profiles SUBJECT RECRUITMENT : Connecting Type 2 Diabetics to Clinical Trials INFORMATION TECHNOLOGY : Cloud Computing Brings Efficiencies to Life Sciences Also in this issue : Biosimilars Development, Funding in Europe, Transforming R&D, Subject Protection in India

External Link - article-800737.pdf

Download Issue PDF
Articles in this issue
Applied Clinical Trials Digital Edition - July 2011
Recruiting Diabetes Subjects
Recruiting Diabetes Subjects
i4-730570-1408614827911.jpg
Eyes Play a Focal Role in Research
i1-730581-1408614790958.jpg
Fighting for Territory and Funding in Europe
i4-730574-1408614814160.jpg
Cloud Computing Efficiency
i1_t-730567-1408614836563.gif
Best Practice for Clinical Monitoring
Personalized Medicine Development
Personalized Medicine Development
i1-730565-1408614841178.jpg
Italian Regulator Prepares for Europe's Top Job
i1_t-730571-1408614824874.gif
Value of Time and Money
i1-730576-1408614807724.jpg
Transforming R&D Through Open Innovation
i1-730578-1408614800154.jpg
Biosimilars Development Raises Research Questions
i1-730579-1408614797073.jpg
Protecting the Vulnerable in India
i4-730569-1408614831350.jpg
Business and News Update July 2011
Recent Videos
Related Content
Preparing to Achieve with Joint Clinical Assessments

Preparing to Achieve with Joint Clinical Assessments

Graham Bell
June 11th 2025
Article

Strategies for sponsors in navigating the European Union's new health technology assessment regulation.

Unifying Industry to Better Understand GCP Guidance

Unifying Industry to Better Understand GCP Guidance

Andy Studna, Senior Editor
May 7th 2025
Podcast

In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.

What We Think We Know: How Overconfidence Derails Clinical Trials

What We Think We Know: How Overconfidence Derails Clinical Trials

Brian S. McGowan, PhD, FACEHP
June 11th 2025
Article

Overcoming the illusion of knowledge in clinical research can enhance decision-making, training, and project success—helping ensure trials run smoothly and effectively.

Site Logo

Unlock Commercial Growth through Data-Driven Patient and HCP Insights Podcast

May 2nd 2025
Podcast
© LASZLO - © LASZLO - stock.adobe.com.

First Patient Dosed in Phase III Trial of Enhertu as First-Line Treatment for Endometrial Cancer

Andy Studna, Senior Editor
June 10th 2025
Article

In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 study for the treatment of patients with HER2-expressing, mismatch repair proficient primary advanced or recurrent endometrial cancer.

Credit: Dr_Microbe | stock.adobe.com. Lung cancer, medical concept, 3D illustration showing cancerous tumor inside human lung

Phase III DeLLphi-304 Trial Finds Imdelltra Significantly Extends Survival in Relapsed Small-Cell Lung Cancer

Davy James
June 10th 2025
Article

Phase III DeLLphi-304 results show T-cell engager Imdelltra (tarlatamab) delivers superior overall survival, improved progression-free survival, and better symptom control compared to chemotherapy in patients with small-cell lung cancer following platinum-based treatment.

© 2025 MJH Life Sciences

All rights reserved.